Ionis Pharmaceuticals (IONS) said Monday that a study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease met its primary endpoint, as well as all key secondary endpoints.
Results showed a "statistically significant" placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80-milligram and 50 mg monthly doses, respectively, the company said.
Olezarsen also showed a favorable safety and tolerability profile, according to Ionis.
The company expects data from the pivotal phase 3 CORE and CORE2 studies assessing olezarsen to treat severe hypertriglyceridemia in Q3.
Triglycerides are a kind of fat the body uses as a source of energy.
Ionis shares were up 1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.